Khaled Selim, MD
Gastroenterology · Loma Linda, CANPI 1174688071
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $46,954 of the $56,740 with a category attached, or 82.8%. 12 manufacturers reported payments, led by Madrigal Pharmaceuticals at 36.1% of the total. Reporting peaked in 2019 at $23,848 and has fallen 61.4% since, to $9,209 in 2025. Among gastroenterology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 101 payments — averaging $561.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Madrigal Pharmaceuticals$20K
- Gilead$19K
- Intercept Pharmaceuticals, Inc.$15K
- Ipsen Biopharmaceuticals, Inc$1K
- AbbVie$935
- Mallinckrodt Hospital Products Inc.$289
- plus $423 from 6 others
What the payments were for
- Speaking & faculty fees$46,95483%
- Travel & lodging$5,67710%
- Food & beverage$4,0767%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Madrigal Pharmaceuticals | 22 | $20,492 |
| Gilead | 31 | $18,680 |
| Intercept Pharmaceuticals, Inc. | 18 | $14,753 |
| Ipsen Biopharmaceuticals, Inc | 3 | $1,168 |
| AbbVie | 16 | $935 |
| Mallinckrodt Hospital Products Inc. | 3 | $289 |
| Novo Nordisk | 3 | $134 |
| E.r. Squibb & Sons, L.L.C. | 1 | $98 |
| ERBE USA Inc | 1 | $79 |
| GSK | 1 | $50 |
| Histosonics, Inc. | 1 | $46 |
| Shionogi Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$56,740 in reported general payments places this provider in the 90th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tacrolimus | 14 | $2,182 |
| Ursodiol | 14 | $2,070 |
| Spironolactone | 11 | $161 |
| Furosemide | 11 | $64 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Loma Linda
- Bennett RothLos Angeles$2.8M
- Douglas NguyenMission Viejo$2M
- Sammy SaabLos Angeles$1.9M
- Kenneth ChangNewport Beach$1.3M
- Joo HwangStanford$1M
- Drew SchembreWalnut Creek$659K
- Quan Nhula Jolla$641K
- Sadeea AbbasiLos Angeles$556K
- Ali RezaieWest Hollywood$519K
- Kenneth BinmoellerSan Francisco$507K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.